ESRRA and prostate cancer: Furthermore, treatments with inhibitors of ERRα (XCT790) and ERG (EIP1) could reduce the protein levels of eNOS in VCaP cells (Fig. 6d), suggesting that both ERRα and ERG could act as the upstream regulators of eNOS in prostate cancer cells and PCSCs.